| Hazard Information | Back Directory | [Uses]
Anticoagulant. | [Clinical Use]
Prophylaxis of DVT in patients undergoing orthopaedic
surgery | [in vivo]
Desirudin (CGP 39393, 0.75-3.0 mg/kg, a bolus plus infusion administration, dogs model of cardiopulmonary bypass) is effective in Inhibiting clot formation[1].
Desirudin (0.01-1 mg/kg, Intravenous injections and subcutaneous injection, rat shunt model) inhibits thrombus development with ED50 values of 0.3 mg/kg (i.v.) and 1.0 mg/kg (s.c.), and inhibits venous stasis thrombosis with ED50 values of 0.01 mg/kg (i.v.) and 0.45 mg/kg (s.c.)[2]. | Animal Model: | Male mongrel dogs model of cardiopulmonary bypass[1] | | Dosage: | 1.0 mg/kg + 0.75 mg/kg/h, 1.0 mg/kg + 1.50 mg/kg/h, 1.0 mg/kg + 2.25 mg/kg/h, 1.0 mg/kg + 3.0 mg/kg/h. | | Administration: | Administered as a bolus plus infusion | | Result: | Inhibited clot formation with no adverse hemodynamic or hematologic effects. |
| Animal Model: | Rat shunt model of thrombus formation on a cotton-thread[2] | | Dosage: | 0.01-1 mg/kg approximately | | Administration: | Intravenous injections, subcutaneous injection | | Result: | Inhibited thrombus development with ED50 values of 0.3 mg/kg (i.v.) and 1.0 mg/kg (s.c.).
Inhibited venous stasis thrombosis with ED50 values of 0.01 mg/kg (i.v.) and 0.45 mg/kg (s.c.).
|
| [Drug interactions]
Potentially hazardous interactions with other drugs
Anticoagulants, antiplatelets, fondaparinux,
NSAIDs, heparin and dextran - increased risk of
bleeding | [Metabolism]
Desirudin is metabolised and excreted by the kidney, and
40-50% of a dose is excreted unchanged in the urine |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
|